Absci Corporation, trading on the Nasdaq under the symbol ABSI, is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics using generative AI. The company is currently in the spotlight due to a significant stock transaction by its Chief Innovation Officer, Busch Andreas. On July 28, 2025, Andreas purchased 50,000 shares of ABSI common stock at $3.04 per share, increasing his total holdings to 327,264 shares.
In addition to this insider transaction, Absci has announced a public offering of its common stock. The company is offering 16.67 million shares at $3.00 per share, aiming to raise approximately $50 million in gross proceeds. This offering is part of Absci's strategy to fund its internally developed therapeutics and invest in its Integrated Drug Creation™ platform. The offering includes a 30-day option for underwriters to purchase an additional 2.5 million shares.
The stock offering is managed by major financial institutions, including Morgan Stanley, J.P. Morgan, Jefferies, and TD Securities (USA) LLC. The proceeds from this offering will support Absci's drug development programs and general corporate purposes, such as working capital. The offering is subject to market conditions, which can impact its success.
Currently, ABSI stock is priced at $2.97, reflecting a 2.77% increase with a $0.08 change. The stock has fluctuated between $2.90 and $3.09 today. Over the past year, ABSI has seen a high of $6.33 and a low of $2.01. The company's market capitalization is approximately $378.9 million, with a trading volume of 9.24 million shares.
